<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211027052886N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-03-07</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Drug holiday method on sexual function in women treated with selective serotonin reuptake inhibitors</public_title>
      <acronym></acronym>
      <scientific_title>The effectiveness of drug holiday method on sexual function in women treated with selective serotonin reuptake inhibitors other than fluoxetine: a randomized clinical trial compared with control group</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-03-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/61666</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Entry to the study will be based on a block table of random numbers based on quadruple blocks, and each time a person enters the study, the evaluator and his / her importer will be unaware of what group the next person will be in. At any time, during contact with another researcher who has a table of numbers, he will be informed about his entry into the control group or intervention.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Sexual side effect with SSRIs.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:  25 female and married patients undergoing  maintenance phase of standard care with one of the  selective serotonin reuptake inhibitors, except fluoxetine , enter the study and intervention is that the patient does not take medication for eight weeks on Tuesdays and Fridays. Also, the mental health assessment of patients will be performed on the basis of questionnaire 28 public health questions (GHQ - 28)in the first two turns and the end of the study. The authentication and monitoring of sexual performance is performed by the women's sexual performance index (FSFI). This assessment is a pre - intervention before intervention for all participants, and then they are told to answer all questions of the questionnaire after 4 and then 8 weeks after the study.to increase the degree of participation of participants and higher accuracy of information, every week by the researcher is called on by the researcher and is followed and followed by the pattern of the medication holiday, the incidence of duty, and the fulfillment of the questionnaire. Intervention 2: Control group:  25 female and married patients undergoing maintenance phase of standard care with  one of the  selective serotonin reuptake inhibitors, except fluoxetine, are studied in the group of  control and continue the drug without altering the type and dose of medicine. Also, the mental health assessment of patients will be performed on the basis of questionnaire 28 public health questions (GHQ - 28)in the first two turns and the end of the study. The authentication and monitoring of sexual performance is performed by the women's sexual performance index (FSFI). This assessment is a pre - intervention before intervention for all participants, and then they are told to answer all questions of the questionnaire after 4 and then 8 weeks after the study.to increase the degree of participation of participants and higher accuracy of information, every week by the researcher is called on by the researcher and is followed and followed by the pattern of the medication holiday, the incidence of duty, and the fulfillment of the questionnaire.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Data about main outcome of study will be published

When:
2024

To whom:
Academic researchers

Conditions:
For scientific goals

Where to obtain:
dr.shivasoraya@gmail.com Dr Shiv Sorya

How to obtain:
Sending an E-mail and reason of request

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Shiva Soraya</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Mansouri Street, Niyayesh Street, Satarkhan Avenue</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613111</zip>
        <telephone>+98 21 6655 1665</telephone>
        <email>dr.shivasoraya@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Shiva Soraya</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Mansouri Street, Niyayesh Street, Satarkhan Avenue</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613111</zip>
        <telephone>+98 21 6655 1665</telephone>
        <email>dr.shivasoraya@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>woman Married lived with husband In maintenance phase of treatment with a SSRI Suffering from sexual side effect</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>50 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Sexual dysfunction before starting the medication
substance dependence and taking another medication with established sexual side effect currently</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F19.981</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:  25 female and married patients undergoing  maintenance phase of standard care with one of the  selective serotonin reuptake inhibitors, except fluoxetine , enter the study and intervention is that the patient does not take medication for eight weeks on Tuesdays and Fridays. Also, the mental health assessment of patients will be performed on the basis of questionnaire 28 public health questions (GHQ - 28)in the first two turns and the end of the study. The authentication and monitoring of sexual performance is performed by the women's sexual performance index (FSFI). This assessment is a pre - intervention before intervention for all participants, and then they are told to answer all questions of the questionnaire after 4 and then 8 weeks after the study.to increase the degree of participation of participants and higher accuracy of information, every week by the researcher is called on by the researcher and is followed and followed by the pattern of the medication holiday, the incidence of duty, and the fulfillment of the questionnaire</i_keyword>
      <i_keyword>Control group:  25 female and married patients undergoing maintenance phase of standard care with  one of the  selective serotonin reuptake inhibitors, except fluoxetine, are studied in the group of  control and continue the drug without altering the type and dose of medicine. Also, the mental health assessment of patients will be performed on the basis of questionnaire 28 public health questions (GHQ - 28)in the first two turns and the end of the study. The authentication and monitoring of sexual performance is performed by the women's sexual performance index (FSFI). This assessment is a pre - intervention before intervention for all participants, and then they are told to answer all questions of the questionnaire after 4 and then 8 weeks after the study.to increase the degree of participation of participants and higher accuracy of information, every week by the researcher is called on by the researcher and is followed and followed by the pattern of the medication holiday, the incidence of duty, and the fulfillment of the questionnaire</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Sexual function. Timepoint: Weeks: 0, 4, 8. Method of measurement: Female Sexual Health Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-10-22</approval_date>
        <contact_name>Ethics committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Iran University of Medical Sciences,Next to Milad Tower, Shahid Hemmat Highway Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
